• Tahoe Therapeutics raised USD 30M, with backers including Amplify Partners, Databricks Ventures, Mubadala Capital, and other major investors.
• Funding will advance Tahoe’s therapeutic programs and launch a partnership model to develop medicines using its Virtual Cell Models dataset.
• Tahoe targets one billion single-cell datapoints, mapping one million drug-patient interactions to enable new precision cancer and disease treatments.
  

Tahoe Therapeutics 

US-Based startup Tahoe Therapeutics secured USD 30 million in new funding. The round was led by Amplify Partners with participation from Databricks Ventures, Wing Venture Capital, General Catalyst, and Civilization Ventures. The round also included participation from Conviction, Overlap Holdings, and AIX Ventures. Furthermore, Abu Dhabi’s Mubadala Capital also joined the funding round. 

“While structural models have accelerated molecular design, they rarely translate to clinical success — a problem that remains one of the biggest challenges in drug development,” said Sunil Dhaliwal, General Partner at Amplify Partners. 

With the new capital, Tahoe aims to advance its own therapeutic programs toward the clinic. It is also launching a new model of collaboration. The company will select a single partner, a pharmaceutical or AI company with complementary strengths, to access the forthcoming dataset. Furthermore, it aims to develop the first medicines powered by virtual cell models, combining Tahoe’s data with the partner’s clinical or modeling expertise.

Dataset

This comes after its launched Tahoe‑100M, the world’s first gigascale perturbative single-cell dataset. The dataset and the models trained on it have already led to the discovery of promising new therapeutic candidates for major cancer subtypes. 

Tahoe is now expanding on that foundation: the company plans to generate one billion single-cell datapoints. Moreover, it aims to to build the definitive foundational dataset for training Virtual Cell Models.  With this, it aims to generate one billion single-cell datapoints, mapping one million drug-patient interactions, a scale previously impossible. Furthermore, the dataset aims to support the discovery of new precision medicines for cancer and beyond. 

“Building Tahoe-100M required us to invent new ways to generate single-cell data. Now, we’re applying that superpower to go 10x further. This next phase is about using these massive datasets to bring about the GPT moment for AI models of human cells, translating insights to clinical readouts, and developing new medicines with much lower clinical failure rates.” said Nima Alidoust, co-founder and CEO of Tahoe Therapeutics.